Jump to content

PSI-6130: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
→top: link Catherine Stedman
 
(8 intermediate revisions by 7 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{orphan|date=September 2010}}

{{Drugbox
{{Drugbox
| verifiedrevid = 451750958
| verifiedrevid = 451750958
Line 6: Line 5:
| image = PSI-6130.svg
| image = PSI-6130.svg
<!--Clinical data-->
<!--Clinical data-->
| tradename =
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
Line 26: Line 25:


<!--Chemical data-->
<!--Chemical data-->
| C=10 | H=14 | F=1 | N=3 | O=4
| C=10 | H=14 | F=1 | N=3 | O=4
| molecular_weight = 259.23 g/mol
| smiles = C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
| smiles = C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
| StdInChI = 1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
| StdInChI = 1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
Line 33: Line 31:
}}
}}


'''PSI-6130''' is an experimental treatment for [[hepatitis C]]. PSI-6130 is a member of a class of [[antiviral drug]]s known as [[nucleoside polymerase]] [[enzyme inhibitor|inhibitors]] that was created by chemist Jeremy L. Clark.<ref>{{cite journal | journal = Journal of Medicinal Chemistry | year = 2005 | volume = 48 | issue = 17 | pages = 5504–8 | pmid = 16107149 | title = Design, synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'C-methylcytidine, a potent inhibitor of hepatitis C virus replication | author = Clark, J.| url = http://pubs.acs.org/doi/abs/10.1021/jm0502788?prevSearch=%255Bauthor%253A%2Bjeremy%2Bl.%2Bclark%255D&searchHistoryKey= | doi = 10.1021/jm0502788|display-authors=etal}}</ref> Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called [[NS5B]].<ref>{{cite journal | journal = Antiviral Chemistry & Chemotherapy | year = 2006 | volume = 17 | issue = 2 | pages = 79–87 | title = Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication |author1=Lieven J Stuyver |author2=Tamara R McBrayer |author3=Phillip M Tharnish |author4=Jeremy Clark |author5=Laurent Hollecker | url = http://www.intmedpress.com/serveFile.cfm?sUID=01f7cbfd-f36a-4ff5-ba6e-3eab3035fa55 |display-authors=etal}}</ref>
'''PSI-6130''' is an experimental treatment for [[hepatitis C]]. PSI-6130 is a member of a class of [[antiviral drug]]s known as [[nucleoside polymerase]] [[enzyme inhibitor|inhibitors]] that was created by chemist Jeremy L. Clark.<ref>{{cite journal | vauthors = Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman PA, Stec WJ, Patterson SE, Pankiewicz KW | display-authors = 6 | title = Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication | journal = Journal of Medicinal Chemistry | volume = 48 | issue = 17 | pages = 5504–8 | date = August 2005 | pmid = 16107149 | doi = 10.1021/jm0502788 }}</ref> Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called [[NS5B]].<ref>{{cite journal | vauthors = Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ | display-authors = 6 | title = Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication | journal = Antiviral Chemistry & Chemotherapy | volume = 17 | issue = 2 | pages = 79–87 | year = 2006 | pmid = 17042329 | doi = 10.1177/095632020601700203 | s2cid = 22710780 }}</ref>


PSI-6130 is currently being developed by [[Hoffmann–La Roche]] as a 3',5'-diisobutyrl ester prodrug, R7128.<ref>{{cite journal |author1=Cole, P. |author2=Castaner, R. |author3=Bolos, J. |title=R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection |journal=Drugs of the Future |volume=34 |issue=4 |pages=282–290 |year=2009 |url=http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1367744&p_IsPs=N}}</ref> R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.<ref>{{cite journal | doi = 10.1016/S0140-6736(10)61384-0 }}</ref>
PSI-6130 is currently being developed by [[Hoffmann–La Roche]] as a 3',5'-diisobutyrl ester prodrug, R7128.<ref>{{cite journal | vauthors = Cole P, Castaner R, Bolos J |title=R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection |journal=Drugs of the Future |volume=34 |issue=4 |pages=282–290 |year=2009 |doi=10.1358/dof.2009.034.04.1367744 |url=http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1367744&p_IsPs=N}}</ref> R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.<ref>{{cite journal |display-authors=6 |vauthors=Gane EJ, Roberts SK, [[Catherine Stedman|Stedman CA]], Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF |date=October 2010 |title=Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial |journal=Lancet |volume=376 |issue=9751 |pages=1467–75 |doi=10.1016/S0140-6736(10)61384-0 |pmid=20951424 |s2cid=28977802}}</ref>


==References==
== References ==
{{Reflist}}
{{Reflist}}


Line 46: Line 44:
[[Category:Pyrimidones]]
[[Category:Pyrimidones]]
[[Category:NS5B (polymerase) inhibitors]]
[[Category:NS5B (polymerase) inhibitors]]



{{antiinfective-drug-stub}}
{{antiinfective-drug-stub}}

Latest revision as of 02:12, 29 March 2024

PSI-6130
Clinical data
ATC code
  • none
Identifiers
  • 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H14FN3O4
Molar mass259.237 g·mol−1
3D model (JSmol)
  • C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
  • InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
  • Key:NYPIRLYMDJMKGW-VPCXQMTMSA-N
  (verify)

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark.[1] Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B.[2]

PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128.[3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.[4]

References

[edit]
  1. ^ Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, et al. (August 2005). "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504–8. doi:10.1021/jm0502788. PMID 16107149.
  2. ^ Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, et al. (2006). "Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication". Antiviral Chemistry & Chemotherapy. 17 (2): 79–87. doi:10.1177/095632020601700203. PMID 17042329. S2CID 22710780.
  3. ^ Cole P, Castaner R, Bolos J (2009). "R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection". Drugs of the Future. 34 (4): 282–290. doi:10.1358/dof.2009.034.04.1367744.
  4. ^ Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. (October 2010). "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial". Lancet. 376 (9751): 1467–75. doi:10.1016/S0140-6736(10)61384-0. PMID 20951424. S2CID 28977802.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=PSI-6130&oldid=1216104992"